| [1] |
Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues[M]. 4th ed. Lyon: IARC, 2008. |
| [2] |
Cerci JJ, Trindade E, Pracchia LF, et al. Cost effectiveness of positron emission tomography in patients with Hodgkin's lymphoma in unconfirmed complete remission or partial remission after first-line therapy[J]. J Clin Oncol, 2010, 28(8):1415-1421. DOI:10.1200/JCO.2009.25.4367. |
| [3] |
Baba S, Abe K, Isoda T, et al. Impact of FDG-PET/CT in the management of lymphoma[J]. Ann Nucl Med, 2011, 25(10):701-716. DOI:10.1007/s12149-011-0549-0. |
| [4] |
Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma:consensus of the International Conference on Malignant Lymphomas Imaging Working Group[J]. J Clin Oncol, 2014, 32(27):3048-3058. DOI:10.1200/JCO.2013.53.5229. |
| [5] |
Meignan M, Gallamini A, Haioun C, et al. Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010[J]. Leuk Lymphoma, 2010, 51(12):2171-2180. DOI:10. 3109/10428194.2010.529208. |
| [6] |
Meignan M, Gallamini A, Itti E, et al. Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus[J]. Leuk Lymphoma, 2012, 53(10):1876-1881. DOI:10.3109/10428194.2012.677535. |
| [7] |
Barrington SF, Qian W, Somer EJ, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma[J]. Eur J Nucl Med Mol Imaging, 2010, 37(10):1824-1833. DOI:10.1007/s00259-010-1490-5. |
| [8] |
Dann EJ. PET/CT adapted therapy in Hodgkin disease:current state of the art and future directions[J]. Curr Oncol Rep, 2012, 14(5):403-410. DOI:10.1007/s11912-012-0250-z. |
| [9] |
覃春霞, 兰晓莉. PET/CT在恶性淋巴瘤疗效评估中的应用[J].临床内科杂志, 2015, 32(3):166-169. DOI:10.3969/j.issn.1001-9057.2015.03.006. Qin CX, Lan XL. Application of PET/CT in evaluation of curative effect of lymphoma[J]. J Clin Int Med, 2015, 32(3):166-169. doi: 10.3969/j.issn.1001-9057.2015.03.006 |
| [10] |
Kasamon YL, Jones RJ, Wahl RL. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma[J]. J Nucl Med, 2007, 48 Suppl 1:S19-27. |
| [11] |
陈伟华, 冷吉艳. 18F-FDG PET-CT显像对恶性淋巴瘤诊断和分期中的临床应用价值[J].中国实验诊断学, 2010, 14(5):682-684. DOI:10.3969/j.issn.1007-4287.2010.05.016. Chen WH, Leng JY. Clinical utility of 18F-FDG PET-CT in diagnosis and staging of lymphoma[J]. Chin J Lab Diagn, 2010, 14(5):682-684. doi: 10.3969/j.issn.1007-4287.2010.05.016 |
| [12] |
林端瑜, 唐明灯, 李生栩, 等. 18F-FDG PET-CT在霍奇金淋巴瘤疗效评价中的临床价值[J].国际放射医学核医学杂志, 2012, 36(6):352-357. DOI:10.3760/cma.j.issn.1673-4114.2012.06.008. Lin DY, Tang MD, Li SX, et al. A preliminary study on clinical value of 18F-FDG PET-CT in evaluation of efficacy of Hodgkin lymphoma[J]. Int J Radiat Med Nucl Med, 2012, 36(6):352-357. doi: 10.3760/cma.j.issn.1673-4114.2012.06.008 |
| [13] |
Castellucci P, Zinzani P, Pourdehnad M, et al. 18F-FDG PET in malignant lymphoma:significance of positive findings[J]. Eur J Nucl Med Mol Imaging, 2005, 32(7):749-756. DOI:10.1007/s00259-004-1748-x. |
| [14] |
宋玉琴, 朱军. PET/CT在淋巴瘤中的应用价值[J].中华医学杂志, 2012, 92(46):3241-3242. DOI:10.3760/cma.j.issn.0376-2491.2012.46.001. Song YQ, Zhu J. The application value of PET/CT in lymphoma[J]. Natl Med J China, 2012, 92(46):3241-3242. doi: 10.3760/cma.j.issn.0376-2491.2012.46.001 |